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The present study developed and validated an HPLC method for the simultaneous determination of 
artesunate (AS) and mefloquine hydrochloride (MQ) in fixed-dose combination tablets, according to 
ICH guidelines. The chromatographic separation was carried out on an XBridge C18 (250 x 4.6 mm i.d.,  
5 µm particle size, Waters) analytical column. The mobile phase included a 0.05 M monobasic potassium 
phosphate buffer (pH adjusted to 3.0 with phosphoric acid) and acetonitrile (50 + 50, v/v). The flow 
rate was 1.0 mL/min, and the run time was 13 minutes. A dual-wavelength approach was employed: 
AS detection was performed at 210 nm and MQ was detected at 283 nm, using a diode array detector. 
Stability of sample solutions was evaluated for 8 hours after preparation, during which time the solutions 
remained stable. Youden’s test was employed to evaluate robustness. The method proved to be linear 
(r2>0.99), precise (RSD<2.0%), accurate, selective, and robust, proving to be appropriate for routine 
drug quality control analysis.
Uniterms: Artesunate/determination. Mefloquine hydrochloride/determination. High performance liquid 
chromatography/qualitative analysis. Fixed-dose combination tablets/qualitative analysis.
Um método por cromatografia a líquido de alta eficiência para a determinação simultânea de artesunato 
(AS) e cloridrato de mefloquina (MQ) em comprimidos em dose fixa combinada foi desenvolvido e 
validado, de acordo com as normas do ICH. A separação cromatográfica foi realizada com uma coluna 
analítica XBridge C18 (250 x 4,6 mm d.i., partículas de 5 µm, Waters). A fase móvel foi constituída de 
tampão fosfato monobásico de potássio 0,05 M (pH ajustado para 3,0 com ácido fosfórico) e acetonitrila 
(50 + 50, v/v). O fluxo da fase móvel foi de 1,0 mL/min e o tempo de corrida foi de 13 minutos. Utilizaram-
se dois comprimentos de onda: a detecção do AS foi realizada em 210 nm e a de MQ foi realizada em 
283 nm, utilizando-se um detector de arranjo de diodos. A estabilidade das soluções padrão e amostra foi 
avaliada por 8 horas após sua preparação e as soluções permaneceram estáveis nesse período. O teste de 
Youden foi empregado para a avaliação da robustez do método. O método se mostrou linear (r2>0,99), 
preciso (DPR<2,0%), exato, seletivo e robusto, sendo adequado para análises rotineiras de controle de 
qualidade dos medicamentos.
Unitermos: Artesunato/determinação. Cloridrato de mefloquina/determinação. Cromatografia líquida 
de alta eficiência/análise qualitativa. Comprimidos em dose fixa combinada/análise qualitativa.
INTRODUCTION
New antimalarial regimens have been deemed 
necessary ever since the worldwide emergence of 
Plasmodium falciparum’s resistance to drugs used in 
monotherapy (Kremsner, Krishna, 2004). The main 
strategy to reduce and/or prevent antimalarial drug 
resistance is the use of drug combinations (White, 1998). 
The rationale is twofold: clinical efficacy is increased, 
and the evolution of resistance is slowed (Hastings, 2011). 
Artemisinin-based combination therapies (ACTs), such 
as artemether-lumefantrine, artesunate-amodiaquine, 
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artesunate-sulfadoxine-pyrimethamine, and artesunate-
mefloquine are recommended by the World Health 
Organization (WHO) for the treatment of uncomplicated 
P. falciparum malaria (WHO, 2011a). ACT is based on 
the use of two drugs with different modes of action: an 
artemisinin-derivative that rapidly clears asexual blood 
stage parasites and gametocytes, as well as a partner 
drug that has a longer half-life, thus eliminating residual 
parasites (Varotti et al., 2008).
Artesunate(AS)-Mefloquine hydrochloride(MQ)--
ASMQ–fixed-dose combination tablets are Brazil’s ACT 
choice for the treatment of uncomplicated falciparum 
malaria. Two tablet strengths are currently available: 
25 mg of AS and 55 mg of MQ (corresponding to 50 mg 
of mefloquine base) for children and 100 mg of AS and 
220 mg of MQ (corresponding to 200 mg of mefloquine 
base) for adults. The use of AS and MQ in a fixed-dose 
tablet formulation considerably reduces the possible 
appearance of a resistant parasite, given that the parasites 
are never exposed to the artemisinin derivative alone 
and that mefloquine contains a small residual biomass 
to eradicate at a time of maximum blood concentration 
(White, Olliaro, 1996). Chemical structures of AS and MQ 
are shown on Figure 1.
To date, neither pharmacopeial monographs nor 
methods have been reported in scientific literature to 
determine AS and MQ in fixed-dose combination tablets. 
Analytical methods to determine AS and MQ in fixed-
dose combination tablets are needed to evaluate their 
quality in endemic areas, as well as to detect counterfeit 
drug products (Martino, 2010). One method in which to 
determine AS in tablets is described in the International 
Pharmacopoeia (World, 2011b), whereas a method to 
determine MQ in tablets is described in the Brazilian 
Pharmacopeia (Brasil, 2010). Methods for the single 
determination of AS or MQ in tablets were also found 
in prior scientific literature (Nogueira et al., 2011; 
Gaudiano et al., 2006; Ranher et al., 2010). In addition, 
the simultaneous assay of AS and MQ in plasma (Hodel 
et al., 2009) and a method presenting a single extraction 
procedure and two HPLC systems to determine AS and 
MQ in human plasma have been published in the literature 
(Lai et al., 2007).
Hence, the present study aimed to develop and 
validate an HPLC method, using dual-wavelength UV 
detection, to simultaneously quantify AS and MQ in fixed-
dose combination tablets. As AS and MQ present different 
maximum wavelengths in their UV spectra, detection was 
performed at 210 nm (for AS quantification) and 283 nm 
(for MQ quantification). The dual wavelength approach 
eliminated the standard addition procedure performed in a 
previous study of artemether and lumefantrine in a fixed-
dose combination tablet (César et al., 2008). Stability 
of standard and sample solutions was also investigated 
due the instability of AS in aqueous solutions (Gaudin 
et al., 2007). The validated method was applied to the 
analysis of tablets containing the AS and MQ associations 
(25 + 55 mg).
EXPERIMENTAL
Material and reagents
AS and MQ reference standards were purchased 
from U.S. Pharmacopeial Convention (Rockville, MD, 
USA). ASMQ tablets containing 25 mg of AS and 55 mg 
of MQ were produced by Farmanguinhos/FIOCRUZ 
(Rio de Janeiro, Brazil). Concerning croscarmellose 
sodium, microcrystalline cellulose, magnesium stearate, 
opadry white and blue lake FDC 2, all excipients of 
the formulation, were donated by Farmanguinhos/
FIOCRUZ. Acetonitrile was obtained from Tedia 
(Fairfield, OH, USA) and from Honeywell (Seelze, 
Germany), the latter used only in the robustness study. 
Ultrapure water was obtained from a Millipore Direct-Q 
system (Billerica, MA, USA). Monobasic potassium 
phosphate and phosphoric acid were purchased from 
Merck (Darmstadt, Germany).
Instrumental and Analytical Conditions
The HPLC analyses were carried out using an 
Agilent 1100 system (Santa Clara, CA, USA), composed 
of quaternary pump, autosampler, diode array detector 
(DAD), and HP ChemStation Software. Chromatographic 
separat ion was carr ied out  on an XBridge C18 
(250 x 4.6 mm i.d., 5 µm particle size) analytical column 
FIGURE 1 - Chemical structures of artesunate (AS) and 
mefloquine hydrochloride (MQ).
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from Waters (Milford, MA, USA), maintained at 30 oC. UV 
detection was performed at 210 nm for AS quantification 
and at 283 nm for MQ quantification. UV spectra from 200 
to 400 nm were online recorded for peak identification. 
The injection volume for all solutions was 20 μL. The 
optimized mobile phase was a mixture of 0.05 M monobasic 
potassium phosphate (pH adjusted to 3.0 with phosphoric 
acid) and acetonitrile (50 + 50, v/v). To determine k, t0 was 
estimated by injecting a 0.01% (w/v) NaNO3 solution onto 
the chromatograph.
An Agilent 1200 system and an ACE column 
(250 x 4.6 mm i.d., 5 µm particle size) from Advanced 
Chromatography Technologies – ACT (Aberdeen, 
Scotland, UK) were also employed in the robustness study.
Preparation of standard solutions
Approximately 12.5 mg of AS and 27.5 mg of 
MQ reference standards were accurately weighed and 
transferred to a 25 mL volumetric flask, followed by 
the addition of 20 mL of mobile phase. The flask was 
sonicated for 10 minutes and then filled to the mark with 
mobile phase to obtain a solution at 0.5 mg/mL of AS and 
1.1 mg/mL of MQ.
Analysis of fixed-dose combination tablets
Twenty tablets, containing 25 mg of AS and 55 mg 
of MQ each, were crushed, and an accurately weighed 
portion of the powder, equivalent to about 25 mg of AS, 
was transferred to a 50 mL volumetric flask followed by 
the addition of 40 mL of mobile phase. The flask was 
sonicated for 10 minutes and filled to the mark with mobile 
phase, with theoretical sample concentrations of AS and 
MQ registered at 0.5 mg/mL and 1.1 mg/mL, respectively. 
The amounts of AS and MQ in the samples were calculated 
using a one-point calibration. Standard solutions were 
injected five times and sample solutions once. AS and 
MQ peak areas were measured, and their concentration 
was calculated using the average standard response factor 
(peak area divided by standard concentration).
Validation of the method
Selectivity
Spectral purities of AS and MQ chromatographic 
peaks were evaluated using the UV spectra recorded by 
a diode array detector. A solution containing a mixture 
of tablet excipients was also prepared according to the 
sample preparation procedure and injected onto the 
chromatograph to evaluate possible interfering peaks.
Linearity
Standard solutions containing 2.5 mg/mL of AS and 
5.5 mg/mL of MQ were prepared in triplicate. Aliquots of 
these solutions were diluted in the mobile phase to five 
different concentrations: 0.250, 0.375, 0.500, 0.625, and 
0.750 mg/mL of AS and 0.550, 0.825, 1.100, 1.375, and 
1.650 mg/mL of MQ. Calibration curves of concentration 
versus area were plotted, and the obtained data were 
subjected to regression analysis using the least-squares 
method.
Precision
The intra-day precision was evaluated by analyzing 
six samples (n = 6) at 100% of the test concentration 
(0.5 mg/mL of AS and 1.1 mg/mL of MQ). Samples were 
prepared as set forth in Analysis of fixed-dose combination 
tablets. Similarly, the inter-day precision was evaluated on 
two consecutive days (n = 12). The AS and MQ contents 
(% of labeled amount) were determined, and the RSD was 
calculated. A Student’s t test was employed to compare 
the average content of AS and MQ obtained in the two 
consecutive days.
Accuracy
Accuracy was investigated by means of a standard 
addition experiment. Amounts of AS (11.25, 17.50, and 
23.75 mg) and MQ (24.75, 38.50, and 68.75 mg) were 
added to tablet powder, corresponding to 7.5 mg of AS 
and 16.5 mg of MQ (0.3 average tablet weight). The 
mixture was transferred to a 50 mL volumetric flask, 
and the volume was completed with mobile phase. The 
accuracy was investigated at three concentration levels: 
75, 100, and 125 percent of the theoretical concentrations 
of AS and MQ. At each level, the solutions were prepared 
in triplicate, and the recovery percentage was calculated.
Robustness
Method robustness was assessed by determining 
the AS and MQ contents in tablets through a series of 
eight experiments following a factorial design (Youden, 
Steiner, 1975). The seven analytical parameters employed, 
as well as the introduced variations, are shown in Table I. 
A standard and a sample solution were prepared for 
each condition, and were injected three times onto the 
chromatograph. Peak area, retention time, tailing factor, 
theoretical plate number, and the contents of AS and MQ 
in the tablets were evaluated for each condition.
Stability of solutions
A standard and a sample solution were prepared 
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as described above, and were injected onto the 
chromatograph, at each hour, for 8 consecutive hours. 
The presence of additional peaks that could indicate AS 
or MQ degradation and/or the decrease of AS or MQ peak 
areas were evaluated.
RESULTS AND DISCUSSION
Optimization of the chromatographic conditions
Initial experiments were carried out with the 
chromatographic conditions to determine the mefloquine 
hydrochloride content in tablets (Nogueira et al., 2011). 
The mobile phase was a mixture of 0.05 M phosphate 
buffer pH 3.5 and methanol (40 + 60, v/v). MQ and AS 
retention factors (k) were 3.04 and 6.18, respectively. 
The resolution between the two peaks was greater than 
10.0, and the run time was 40 minutes. Methanol presents 
a UV cutoff at 205 nm, which could therefore not be 
employed in the mobile phase to determine the AS content, 
given that AS only presents UV absorption in the initial 
wavelengths of the UV spectrum (200-220 nm) due to the 
absence of chromophores in its structure. Thus, methanol 
was replaced by acetonitrile in the mobile phase. The 
acetonitrile proportion was adjusted to 50% to maintain 
the same solvent strength of the previous mobile phase 
(methanol + buffer). The acetonitrile proportion was 
calculated using a nomograph.
A simultaneous quantification of AS and MQ, 
using the wavelength of 210 nm, proved to be impossible 
due to the excessive broadening of the MQ peak at this 
wavelength. Thus, simultaneous quantification proved to 
be possible, using a wavelength of 210 nm to quantify 
AS and a wavelength of 283 nm to quantify MQ. The 
run time was 13 minutes, and the retention factors (k) 
for MQ and AS were approximately 0.66 and 3.26, 
respectively. The resolution between MQ and AS peaks 
was 6.9.
Method Validation
Selectivity
Peak purity of higher than 99.0% was obtained 
for AS in the chromatograms of sample solutions, 
demonstrating that other compounds did not co-elute. MQ 
peak purity could not be assessed due to the large analyte 
concentration used. The chromatograms obtained with the 
mixture of tablet excipients showed no interfering peaks 
in the same retention time of AS and MQ. The overlaid 
chromatograms of the sample solution and the mixture of 
excipients, at 283 nm and at 210 nm, are shown in Figure 
2 and Figure 3, respectively.
Linearity
A linear correlation was found between the peak 
areas and the concentrations of AS and MQ in the assayed 
range. The regression analysis data are shown in Table II. 
The regression coefficient (r2) obtained in this phase was 
higher than 0.99 for both compounds, which attests to the 
linearity of the method.
Precision
Mean contents of AS and MQ in the intra-day 
precision analyses (n=6) was 96.17% (RSD=1.38%) 
and 100.07% (RSD=1.41%) of their labeled amounts, 
respectively. For the inter-day precision (n=12), the 
mean contents obtained were 96.39% (RSD=1.19%) and 
100.00% (RSD=1.01%) for AS and MQ, respectively. The 
RSD values below 2.0% indicated the high-level precision 
of the method.
Accuracy
Accuracy was investigated by means of a standard 
addition experiment. Table III shows both the expected 
concentrations of AS and MQ and the recovery percentages. 
All values were within the specified limits, between 98.0 
and 102.0% of the theoretical concentration.
TABLE I - Analytical parameters and variations for the robustness evaluation of the chromatographic method for simultaneous AS 
and MQ quantification
Parameter Nominal condition Variation
Acetonitrile concentration in the mobile phase 50% 47%
pH buffer 3.0 3.5
Column temperature 30 oC 35 oC
Mobile phase flow rate 1.0 mL/min 1.2 mL/min
Column supplier Waters ACE
Acetonitrile supplier Tedia Honeywell
Chromatograph model Agilent 1100 Agilent 1200
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TABLE II - Overview of the linearity data for AS and MQ
Regression parameter Artesunate Mefloquine hydrochloride
r2 0.9997 0.9997
Slope ± SE 913.9 ± 4.716 16080 ± 76.00
Intercept ± SE -6.328 ± 2.547 36.71 ± 89.39
RSD, % 0.86 0.51
Concentration range (mg/mL) 0.25 – 0.75 0.55 – 1.65
Number of points 5 5
FIGURE 2 - (A) - Overlay of the chromatogram of the sample solution (full line, λ = 210 nm) and the chromatogram of the mixture 
of excipients (dotted line), optimized mobile phase, showing both mefloquine hydrochloride (MQ) and artesunate (AS) peaks. 
(B) - overlay of the chromatogram of the sample solution (full line, λ = 283 nm) and the chromatogram of the mixture of excipients 
(dotted line), using the optimized mobile phase, showing the mefloquine hydrochloride (MQ) peak.
Robustness
Effects of the variation of analytical parameters in 
content, retention time, tailing factor, and theoretical plate 
number are shown in Table IV. In general, the variation 
of the flow rate and the column supplier were responsible 
for the greatest differences in the plate number for AS and 
MQ. Other factors remained practically unchanged.
Stability of solutions
No changes in the retention time could be observed 
for AS and MQ peaks after 8 hours. Likewise, no additional 
peaks were observed. A negligible reduction (about 1.2%) 
of the AS peak area was observed when the initial peak 
area (zero time) and the area of AS peak after 8 hours of 
preparation were compared. Despite this small reduction 
in the AS peak area, the recommendation was to inject the 
solutions as soon as they had been prepared. MQ peak areas 
remained practically unchanged after 8 hours of analysis.
Analysis of fixed-dose combination tablets
Samples of ASMQ fixed-dose combination tablets 
containing 25 mg of AS and 55 mg of MQ were analyzed 
F. H. A. Nogueira, N. F. A. Reis, P. R. Chellini, I. C. César, G. A. Pianetti842
using the validated method. The samples presented AS and 
MQ contents that proved to be very close to the labeled 
amount. The AS content in samples varied from 94.12% 
to 97.99%, while the MQ content varied from 97.80% to 
102.25%.
CONCLUSION
This study is the first report which simultaneously 
quantifies the artesunate and mefloquine hydrochloride 
content in fixed-dose combination tablets. The method 
proved to be selective, linear, precise, accurate, and robust. 
In addition, the two drugs were separated by an adequate 
run time of 13 minutes. The developed method proved 
to be a simple and suitable technique to quantify these 
antimalarials and can therefore be employed for routine 
quality control analysis.
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TABLE III - Results of the recovery analysis of AS and MQ in tablets
Artesunate Mefloquine hydrochloride
Concentration 
level
Expected 
concentration 
(mg/mL)
Found 
concentration 
(mg/mL)
Recovery (%)
Average 
recovery (%); 
RSD (%)
Expected 
concentration 
(mg/mL)
Found 
concentration 
(mg/mL)
Recovery (%)
Average 
recovery (%); 
RSD (%)
75% 0.3733 0.3712 99.44 99.34; 0.15 0.8425 0.8434 100.10 99.89; 0.18
0.3725 0.3703 99.41 0.8468 0.8449 99.78
0.3812 0.3781 99.17 0.8573 0.8555 99.79
100% 0.5175 0.5178 100.06 100.09; 0.05 1.1039 1.1068 100.26 100.36; 0.12
0.4941 0.4948 100.15 1.1027 1.1062 100.31
0.5214 0.5217 100.06 1.0957 1.1011 100.49
125% 0.6124 0.6148 100.39 100.55; 0.13 1.4071 1.4077 100.04 100.27; 0.21
0.7071 0.7113 100.61 1.4132 1.4181 100.35
0.6266 0.6206 100.64 1.4502 1.4564 100.43
TABLE IV - Effects of the analytical parameters in content, retention time (Rt), tailing factor (T), and theoretical plate number (N) 
of the chromatographic method for AS and MQ quantification
Effect
Artesunate Mefloquine hydrochloride
Content (%)* Rt (min)* T* N* Content (%)* Rt (min)* T* N*
Acetonitrile concentration 
in the mobile phase
101.83-100.79 
= 1.04
9.55-12.08 
= -2.53
1.08-1.08 
= 0.00
17055-17082 
= -27
101.47-101.27 
= 0.20
3.73-4.38 
= -0.65
2.45-2.83 
= -0.38
3797-3709 
= 88
pH buffer 100.82-101.80 
= -0.98
12.09-9.53 
= 2.56
1.08-1.08 
= 0.00
16946-17190 
= -244
101.11-101.63 
= -0.52
4.37-3.75 
= 0.62
2.78-2.50 
= 0.28
3776-3730 
= 46
Column temperature 100.72-101.90 
= -1.18
11.59-10.03 
= 1.56
1.07-1.08 
= -0.01
16662-17474 
= -812
101.20-101.54 
= -0.34
4.20-3.91 
= 0.29
2.72-2.55 
= 0.17
3711-3796 
= -85
Mobile phase flow rate 101.85-100.77 
= 1.08
9.80-11.82 
= -2.02
1.08-1.08 
= 0.00
17576-16560 
= 1016
101.48-101.26 
= 0.22
3.90-4.21 
= -0.31
2.49-2.79 
= -0.30
3979-3527 
= 453
Column supplier 101.69-100.93 
= 0.76
9.48–12.15 
= -2.67
1.10-1.05 
= 0.05
17813-16323 
= 1490
101.41-101.33 
= 0.08
3.77-4.34 
= -0.57
2.55-2.73 
= -0.18
3651-3856 
= -205
Acetonitrile supplier 100.80-101.82 
= -1.02
11.63-9.99 
= 1.64
1.08-1.08 
= 0.00
16892-17244 
= -352
101.25-101.49 
= -0.24
4.28-3.84 
= 0.44
2.74-2.54 
= 0.20
3740-3766 
= -26
Chromatograph model 101.71-100.91 
= 0.80
9.88-11.75 
= -1.87
1.09-1.06 
= 0.03
17254-16882 
= 372
101.55-101.19 
= 0.37
3.82-4.29 
= -0.47
2.55-2.72 
= -0.17
3745-3762 
= -17
*Average of the values obtained at nominal conditions – average of the values obtained at altered conditions.
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